Great progress has been made to advance Alzheimer’s and dementia research, providing hope to families in the midst of a terrible disease. And now that the Food and Drug Administration (FDA) has approved Alzheimer’s treatments to slow its progression at an early stage, it’s lifted that hope higher. 

Thanks to relentless AIM advocacy and bipartisan support from congressional champions, the Centers for Medicare & Medicaid Services (CMS) announced they will enable coverage of FDA traditionally approved Alzheimer’s treatments through a low touch registry. We remain committed to working with policymakers to ensure existing and emerging treatments are accessible and affordable for everyone.